PureTech Health PLC PureTech Announces New Corporate HQ/Internal Labs
June 20 2019 - 2:00AM
RNS Non-Regulatory
TIDMPRTC
PureTech Health PLC
20 June 2019
20 June 2019
PureTech Health plc
PureTech Establishes New Corporate Headquarters in Boston's
Seaport District to Support Expansion and Acceleration of Internal
R&D Pipeline
Company will continue to leverage leadership in Brain-Immune-Gut
axis biology to develop novel categories of therapeutics
BOSTON, June 20, 2019 - PureTech Health plc (LSE: PRTC), an
advanced biopharmaceutical company developing novel medicines for
dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced a
new corporate headquarters and labs in Boston's Seaport District.
The state-of-the-art, integrated office and laboratory space will
support the Company's plans to expand and accelerate development of
its internal R&D pipeline, which is centred on lymphatic
targeting and tissue-selective immunomodulation for the potential
treatment of immune and central nervous system disorders, lymphatic
conditions, and cancers.
"The PureTech team has initiated and advanced highly
differentiated product candidates initially targeting serious
disorders of the brain, immune system, and gastrointestinal tract,
and has progressed more than two dozen product candidates from
discovery through various points of validation, including one all
the way through FDA regulatory clearance. It is through this track
record of execution that we have built our leadership position
around brain-immune-gut "BIG" axis biology and identified the
platforms that form the basis of our internal R&D pipeline
programs," said founder and CEO Daphne Zohar. "PureTech's expanded
presence in the world's premier biotech and biopharmaceutical
R&D ecosystem reflects our commitment to leveraging this unique
expertise around the BIG axis with the goal of bringing
transformational new medicines to patients."
PureTech's internal R&D pipeline includes several programs
that harness the lymphatic system, which plays a crucial role in
programming immune cells for precise functions and trafficking them
to specific tissues. These programs include proprietary
lymphatic-targeting platforms leveraging milk derived exosomes and
lipid cloaking technologies, as well as approaches to modulate
lymphatic flow and vessel dysfunction. PureTech has entered into
research collaborations with two major pharmaceutical companies
leveraging two of these platforms with partners' specific product
candidates or modalities during the past 12 months.
PureTech is also advancing two, first-in-class, fully-human
monoclonal antibodies (mAbs) targeting Galectin-9 (LYT-200) and
immunosuppressive <GAMMA> 1 (gamma delta) T cells (LYT-210)
for the treatment of cancers that currently do not respond or
respond poorly to approved immunotherapies. These unique mAbs
target foundational mechanisms of tumoral immune escape and
immunosuppression and have been tested as single agents as well as
in combination with anti-PD1 in a variety of preclinical murine and
human-derived ex vivo models. As such, PureTech believes they
represent novel additions to the armamentarium of immuno-oncology
agents, with potential application across multiple solid tumours,
including malignancies that historically have proved difficult to
treat. PureTech expects to file an investigational new drug (IND)
application for its lead immuno-oncology program, LYT-200, in the
first half of 2020.
"Tissue-selective, rather than systemic, immunomodulation is a
powerful new avenue for more tailored medicines, and cutting-edge
research is validating the lymphatic system as an important highway
for immune activity across countless conditions," said chief
scientific officer Joe Bolen, PhD. "At PureTech, we are proud to
have built a world-class team of researchers, collaborators, and
advisers around these areas to advance our scientific vision. The
consolidation and colocation of our formerly Cambridge- and
Boston-based labs into this new state-of-the-art facility will
support the continued expansion and rapid advancement of this
vision as we build out our internal pipeline."
PureTech's new offices and labs are located at 6 Tide Street in
Boston. The Company's facility in the Back Bay neighbourhood of
Boston will continue to house several of its affiliates.
About PureTech
PureTech Health (LSE: PRTC) is an advanced biopharmaceutical
company developing BIG medicines for dysfunctions of the
Brain-Immune-Gut axis. The Company has gained deep insights into
the connection between these systems and the resulting role in
diseases that have proved resistant to established therapeutic
approaches. By harnessing this emerging field of human biology,
PureTech is developing new categories of medicines with the
potential to have great impact on people with serious
disorders.
PureTech is advancing a rich pipeline of innovative therapies
with an unbiased, non-binary, and capital efficient R&D model
across its affiliates and its internal R&D pipeline. PureTech's
affiliates include seven clinical-stage platforms, including one
product that has been cleared by the US Food and Drug
Administration (FDA) and a second product candidate that has been
filed with the FDA for review, and several other novel preclinical
programs. The PureTech pipeline includes ground-breaking platforms
and therapeutic candidates that were developed in collaboration
with some of the world's leading experts.
PureTech's internal pipeline is centred on lymphatic targeting
and tissue-selective immunomodulation for the potential treatment
of immune and central nervous system disorders, lymphatic
conditions, and cancers. The Company is advancing multiple
platforms to enable oral administration of therapies directly into
the lymphatic system, regulate lymphatic flow and function, and
target immunosuppressive mechanisms in oncology. For more
information, visit www.puretechhealth.com or connect with us on
Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Tom Donovan
+1 617 651 3156 +44 (0) 20 3727 1000 +1 857 559 3397
amt@puretechhealth.com ben.atwell@FTIconsulting.com tom@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGGUCPQUPBGBB
(END) Dow Jones Newswires
June 20, 2019 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024